Fig. 2.

Efficacy of anti-VEGF-A Mabs in human tumor xenografts implanted s.c. into RAG2 KO; hum-X VEGF KI double-homozygous mice. (A–D) Prevention studies. (E–H) Intervention studies. (A) Growth curves of Calu-6 tumors. Control anti-Ragweed (Anti-Rag), B20–4.1, G6–31, bevacizumab (Beva) or Y0317 Mabs were administered at 5 mg/kg, i.p., twice weekly. (B). Terminal weights of Calu-6 tumors from experiment in A at day 70 of treatment. Control animals were killed at day 44. Tumors from B20-4.1- and G6-31-treated animals had significantly lower weight than the bevacizumab group. (C) Growth curves of human HT29 colorectal carcinoma cells. (D) Terminal weights of HT29 tumors from the experiment in C as determined at day 67. Controls were killed at day 33. (E) Growth curves of Calu-6 tumors in which treatment was initiated after tumor volumes reached ≈400 mm³ (regression study). (F) Terminal tumor weights of Calu-6 tumors in E were determined at day 63. Controls were harvested at day 42. (G) Growth curves of human HM7 colorectal tumor. Similar to E and F, antibody treatment was initiated after tumor volumes reached ≈400 mm³. (H) Terminal weights of HM7 tumors determined on day 61. Controls were killed at day 19. Data shown are Means ± SEM. ∗, Significant difference (P < 0.05) compared with the bevacizumab group.